Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: concerning (1000)

Tarlatamab (EAMS)

Description: Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) Tarlatamab (EAMS) Regimen • SCLC – Tarlatamab (EAMS) Indication • Tarlatamab is indicated as m
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Tarlatamab-EAMS-Ver-1.0.pdf

UHS No PO No Pay policy letter December 2023 revised PO format

Description: Accounts Payable – Mailpoint 320 University Hospital Southampton NHS Foundation Trust Southampton General Hospital Tremona Road Southamp
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Finance/UHS-No-PO-No-Pay-policy-letter-December-2023-revised-PO-format.pdf

Lazy eye in children - patient information

Description: This factsheet contains information about the two most common treatment options for a lazy eye.
Url: /Media/UHS-website-2019/Patientinformation/Eyes/Childrens-eyes/Lazy-eye-in-children-1783-PIL.pdf

End of life care strategy - patient information

Description: A strategy for end of life care.
Url: /Media/UHS-website-2019/Patientinformation/Bereavement-and-end-of-life/End-of-life-care-strategy-3687-PIL.pdf

Florence FAQs_v1.0

Description: Florence FAQ’s Introduction During the 2023 MHRA inspection UHS received a ﬁnding and some advice regarding working electronically for clinical
Url: /Media/Southampton-Clinical-Research/Downloads/Florence-FAQs-v1.0.pdf

People and OD Committee ToR September 2024

Description: People and Organisational Development Committee Terms of Reference Date Issued: 10 September 2024 Review Date: Aug
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/People-and-OD-Committee-ToR-September-2024.pdf

Workforce Race Equality Standard annual report 2024

Description: Executive Summary WRES Data has been submitted by the Trust since 2015 and progress is reviewed against the nine indicators contained
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/UHS-WRES-report-2024.pdf

WDES report and action plan 2024

Description: Workforce Disability Equality Standard Annual Report 2024 1 Executive Summary The Workforce Disability Equality Standard (WDES) is a set of ten
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/UHS-WDES-report-and-action-plan-2024.pdf

EC-PPH Cyclophosphamide Epirubicin Paclitaxel Pertuzumab Trastuzumab

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL-PERTUZUMABTRASTUZUMAB (EC-PPH) Regimen • Breast Cancer – Cyclophosphamide-Epirubicin-Paclitaxel-PertuzumabTrastuzumab (EC-PPH) Indication • Neo
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-PPH-Cyclophosphamide-Epirubicin-Paclitaxel-Pertuzumab-Trastuzumab.pdf

Carboplatin-Docetaxel-Pertuzumab-Trastuzumab_IV-SC

Description: Chemotherapy Protocol BREAST CANCER CARBOPLATIN (AUC6)-DOCETAXEL- PERTUZUMABTRASTUZUMAB (IV/SC) Regimen • Breast Cancer – Carboplatin (AUC6)-Docetaxel-Pertuzumab-Trastuzumab (IV/SC) Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Carboplatin-Docetaxel-Pertuzumab-Trastuzumab-IV-SC.pdf

231 to 240 of 327

Previous … 22 23 24 25 26 … Next